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Background: A Phase II, multicentre, randomised, double-blind, placebo-controlled, crossover trial comparing the
24-h forced expiratory volume in 1 s (FEV1) time profile after 3 weeks’ treatment with once-daily (QD) or twice-daily
(BID) olodaterol (at the same total daily dose) versus placebo delivered via Respimat® in patients with moderate to
severe asthma.
Methods: Patients were randomised to different sequences of olodaterol with 2-week washout, either as a total
daily dose of 5 μg (5 μg QD [AM] or 2.5 μg BID) or placebo, or 10 μg (10 μg QD [AM] or 5 μg BID) or placebo.
Primary end point was FEV1 area under the curve from 0 to 24 h (AUC0–24) response (defined as change from study
baseline FEV1) after 3 weeks. Key secondary end points were FEV1 AUC0–12 and AUC12–24 responses.
Results: Two hundred and six patients received treatment. All olodaterol treatments demonstrated statistically
significant improvements in FEV1 AUC0–24 response at 3 weeks versus placebo (p < 0.0001); adjusted mean treatment
difference versus placebo was 0.191 L for olodaterol 2.5 μg BID (95 % confidence interval [CI] 0.152, 0.229), 0.150 L for
5 μg QD (95 % CI 0.111, 0.189), 0.228 L for 5 μg BID (95 % CI 0.190, 0.266) and 0.209 L for 10 μg QD (95 % CI 0.170,
0.247). These results were supported by the key secondary end points. Olodaterol 5 μg QD provided numerically lower
mean values for 24-h bronchodilation than olodaterol 2.5 μg BID (p = 0.0465), with no statistically significant difference
between treatment with olodaterol 10 μg QD and 5 μg BID. No relevant differences in morning and evening peak
expiratory flow or Asthma Control Questionnaire scores at 3 weeks were observed between different doses and
regimens. Adverse events were generally mild to moderate and comparable between groups.
Conclusions: All doses and dose frequencies provided adequate 24-h bronchodilation superior to placebo. Based on
the results of this study, it would be reasonable to include both posologies of 5 μg olodaterol daily (5 μg QD or 2.5 μg
BID, both delivered in two puffs per dose from the Respimat® inhaler) in subsequent studies. Further studies are
necessary to confirm the optimum dosing regimen in asthma. No safety concerns were identified.
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Long-acting β2-agonists (LABAs) are used in combin-
ation with inhaled corticosteroids (ICS) as controller
medication for asthma, and have been shown to improve
lung function and symptom scores, and reduce the risk
of severe exacerbations [1]. Bronchodilators are also well
established as treatment for chronic obstructive pulmon-
ary disease (COPD); LABAs have demonstrated signifi-
cant improvements in lung function, health-related
quality of life and exacerbations in this setting [2, 3].
First-generation LABAs, such as formoterol and sal-
meterol [4, 5], have a 12-h duration of action that re-
quires a twice-daily (BID) dosing schedule. More
recently, research efforts have focused on the develop-
ment of LABAs with a longer duration of action, which
may allow for more convenient once-daily (QD) dosing,
potentially improving adherence [6, 7]. Olodaterol is a
novel LABA, characterised by high β2 selectivity and a
near full-agonist profile at β2 adrenoceptors, with a dur-
ation of action over 24 h demonstrated by preclinical
studies [8]. Effective 24-h bronchodilation with oloda-
terol has subsequently been confirmed by single-dose
studies in both asthma and COPD [9, 10], along with
Phase II studies in COPD investigating four doses of QD
olodaterol [11] and a comparison of QD and BID dosing
[12] and a large Phase III programme in COPD [13–16].
These data also demonstrated an acceptable tolerability
profile and no safety concerns were identified.
Dosing and posology have been the focus of recent
discussion in development of new bronchodilators.
Firstly, the goal of defining the lowest effective dose to
minimise safety risk is of particular importance in view
of specific safety considerations for LABA use in asthma
[17]. Secondly, while demonstration of 24-h duration of
action affords the opportunity to consider QD dosing,
assessment of lung function trough measurements alone
may not be sufficient to demonstrate that QD dosing is
the most appropriate regimen. Specific clinical compari-
son of different doses and posologies (e.g. QD versus
BID) over a 24-h period is the most appropriate method
for determining the optimum dose and dosing schedule.
The inhaled anticholinergic aclidinium bromide serves
as a recent example of a drug developed as a QD treat-
ment [18] but then reassessed at later stages of clinical
development and finally approved as a BID drug at a dif-
ferent dose [19].
This study has been designed as a posology study for
olodaterol in asthma in combination with maintenance
therapy with ICS and forms part of a wider series of
studies exploring the optimum dose and regimen of
olodaterol in both asthma and COPD. One study investi-
gated single-dose olodaterol [9] while two Phase II dose-
finding studies were conducted using different designs in
moderate asthma. One 4-week, parallel-group study(NCT00467740) demonstrated significant benefits with
olodaterol versus placebo, and dose ordering with regards
to peak expiratory flow (PEF) but not in forced expiratory
volume in 1 s (FEV1), the primary end point of the study
[20]. A subsequent incomplete-block crossover study with
4-week treatment periods (NCT01013753) reported sig-
nificant benefits with olodaterol compared to placebo, and
dose ordering observed with FEV1 and PEF [21].
This paper describes the results of our study that was
designed to investigate dosing frequencies by comparing
the 24-h FEV1 profile of the same olodaterol daily dose
administered in either a QD or BID schedule, i.e. 5 μg QD
in the morning versus 2.5 μg BID and 10 μg QD in the
morning versus 5 μg BID in patients with moderate to se-
vere persistent asthma on maintenance ICS. It is similar in
design to a study carried out in patients with COPD
(NCT00846768) [12] but with an additional placebo com-
parison. Total daily doses of 5 and 10 μg were chosen for
evaluation as, based on an integrated view of earlier data
for QD olodaterol, these doses are approaching the plat-
eau on the dose-response curve [11, 21].
Methods
Patients
Patients were randomised if they met the following
main inclusion criteria: aged ≥18 and ≤70 years; a diag-
nosis of moderate to severe asthma according to the
Global Initiative for Asthma [22]; pre-bronchodilator
FEV1 ≥60 % and <90 % of predicted FEV1; an increase
in FEV1 of ≥12 % and ≥200 mL 15 min after adminis-
tration of 400 μg salbutamol at screening visit; non-
smokers or ex-smokers with a history of <10 pack-years
(and smoking cessation ≥1 year prior to enrolment). Pa-
tients must have been taking ICS for ≥12 weeks prior
to screening and a stable dose for >6 weeks (either
medium- to high-dose ICS, or low- to high-dose ICS in
fixed-dose combination with a LABA). Patients previously
receiving fixed-dose combinations of LABA and ICS were
required to demonstrate stability while continuing to re-
ceive the equivalent ICS monotherapy for ≥48 h prior to
screening visit. Key exclusion criteria included: patients
currently diagnosed with a significant disease other than
asthma (determined by the investigator as any condition
that may put the patient at risk if they entered the
study, may influence the results of the study or may
cause concern regarding the patient’s ability to par-
ticipate in the study); patients who had been hospi-
talised for an asthma exacerbation within 3 months
or admitted to an intensive care unit due to asthma
within the past 3 years; and patients with a history
of myocardial infarction, cor pulmonale or cystic fi-
brosis. The study was performed in accordance with
the Declaration of Helsinki, International Conference
on Harmonisation Good Clinical Practice Guidelines
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protocol was approved by the ethics research board
of the respective institutions and signed consent was
obtained from all patients.
The Independent Ethics Committee was Ethikkommittee
der Landesärztekammer Hessen, Frankfurt am Main,
Germany and the competent authority (Bundesinstitut
für Arzneimittel und Medizinprodukte [BfArM], Bonn,
Germany) approved the study on 23 Feb 2011.
Study design
This was a Phase II, multicentre, randomised, placebo-
controlled, double-blind, three-period, complete-block,
crossover study registered with ClinicalTrials.gov
(NCT01311661). After an initial screening visit, patients
entered a screening period of 2 weeks to ensure clinical
stability. Eligible patients were randomly assigned to re-
ceive a three-period treatment sequence comprising 5 μg
QD olodaterol (taken in the morning), 2.5 μg BID oloda-
terol and placebo in a random order, or a three-period
treatment sequence comprising 10 μg QD olodaterol
(taken in the morning), 5 μg BID olodaterol and placebo
in a random order. There were six possible sequences of
olodaterol QD, olodaterol BID and placebo for each of the
two total daily doses, which ensured that each treatment
appeared in each period the same number of times, and
each treatment followed every other treatment the same
number of times. Patients received each dose regimen for
3 weeks, with a 2-week washout period between regimensFig. 1 Study design. All patients received three dose regimens; each w
total daily dose group received one of six possible sequences of oloda
daily dose group received one of six possible sequences of olodaterol
throughout the study, with posology determined by former use. If adm
take study treatment followed by ICS(Fig. 1). Treatment was delivered via the Respimat®, with
each administration of olodaterol comprising two actua-
tions. All patients were required to take ICS throughout
the trial as background medication, as previously instructed
by their prescribing physician (BID, QD in the morning
or QD in the evening). If administrations coincided, pa-
tients were instructed to take the study medications
first followed by the ICS.
Assessments
Spirometry was conducted according to American
Thoracic Society and European Respiratory Society rec-
ommendations [23]. Identical spirometry equipment
was provided to sites for use in clinic measurements.
The qualifying pulmonary function test was conducted
at screening. Pulmonary function testing (FEV1, forced
vital capacity [FVC] and PEF) was performed at 1 h and
10 min prior to trial drug inhalation for the morning
dose at all visits, ≤3 h post-dose at the start of each 3-
week treatment period (weeks 0, 5 and 10 relative to
study baseline) and ≤24 h after inhalation (00:30, 01:00,
02:00, 03:00, 04:00, 06:00, 08:00, 10:00, 11:50, 12:30,
13:00, 14:00, 22:00, 23:00, 23:50 h) at the end of each 3-
week treatment period (weeks 3, 8 and 13 relative to
study baseline), with a period for night sleep. The pri-
mary end point was FEV1 area under the curve from 0
to 24 h (AUC0–24) response at 3 weeks; this was defined
as FEV1 AUC0–24 divided by 24 to report in litres minus
the study baseline mean FEV1 value. The two keyas separated by a 2-week washout period. Patients in the 5 μg
terol 2.5 μg BID, 5 μg QD and placebo. Patients in the 10 μg total
5 μg BID, 10 μg QD and placebo. Patients continued taking ICS
inistration of ICS and study treatment coincided, patients were to
Beeh et al. Respiratory Research  (2015) 16:87 Page 4 of 12secondary end points were calculated in a similar
fashion: FEV1 area under the curve from 0 to 12 h
(AUC0–12) response and FEV1 area under the curve
from 12 to 24 h (AUC12–24) response, all assessed at
the end of each 3-week treatment period. Peak values
within 24 h post-dose were defined as the maximum
available value between the planned time points 00:30
and 23:50 h after last morning trial-drug inhalation
(inclusive), while trough values were defined as the
mean of the available values at the planned time
points 23:00 and 23:50 h. Similar end points were de-
fined for FVC and PEF.
Daily data on asthma symptoms, night-time awak-
enings, study medication use during treatment period,
ICS medication use, amount of rescue medication
(salbutamol) use, and morning and evening PEF and
FEV1 were recorded using an electronic peak flow
meter with integral patient diary and reviewed by the
investigator at each visit. The Asthma Control Ques-
tionnaire [24] was completed at screening and weeks
0, 3, 8, 13 and 15, relative to study baseline.
Adverse events (AEs) and serious AEs were moni-
tored throughout the trial at each patient visit. Vital
signs, 12-lead electrocardiogram and laboratory tests
were also monitored throughout the study, and re-
ported as AEs if they were not associated with a
symptom or a diagnosis already reported as an AE.Table 1 Baseline patient demographics (treated set)




Median (range) age, years 44 (19–69)
Age group, n (%)
<40 years 73 (35.4)
40–50 years 66 (32.0)
51–65 years 60 (29.1)




Smoking history, n (%)
Never smoked 144 (69.9)
Ex-smokera 62 (30.1)
Mean FEV1, L (standard deviation)
Pre-bronchodilatorb 2.433 (0.619)
Post-bronchodilatorc 2.966 (0.791)
aCigarette smoking history of <10 pack-years and smoking cessation ≥1 year
prior to enrolment
b10 min before administration of 400 μg salbutamol
c10–15 min after administration of 400 μg salbutamol, n = 205
FEV1 forced expiratory volume in 1 sStatistical analysis
A total sample size of 180 randomised patients was
planned to provide ≥90 % power to detect a difference
in means of 0.10 L between any one of the active treat-
ments and placebo for the primary end point of FEV1
AUC0–24, assuming a standard deviation for the paired
differences of 0.25 L and allowing for approximately
20 % of patients to be non-evaluable.
The full analysis set (FAS) was defined as all patients
who received at least one dose of study treatment, for
whom a study baseline FEV1 value was available and
who had at least one post-dose FEV1 value recorded at
an end-of-treatment visit for at least one crossover
period. The FAS was used as the basis for the efficacy
analyses, including the primary analysis of the primary
end point. A per-protocol set was defined (from which
patients with important protocol violations were ex-
cluded) and was used to perform a sensitivity analysis on
the primary end point.
Results for all patients receiving placebo were pooled
for the primary analysis, irrespective of whether they re-
ceived the lower or higher olodaterol daily dose accord-
ing to the randomised treatment sequence, to use all
available data and increase the precision of the estimates.
A post hoc sensitivity analysis was also performed on theFAS with placebo split according to treatment sequence
(i.e. within each separate complete-block design).
FEV1 AUC0–24 response was analysed in the FAS
using a mixed model for crossover studies with ‘treat-
ment’, ‘period’ and ‘study baseline FEV1’ as fixed ef-
fects and ‘patient’ as a random effect. The adjusted
mean difference between each olodaterol dose/fre-
quency and placebo was calculated using this model,
along with the associated p values and 95 % confi-
dence intervals (CIs). Secondary end points were also
analysed in the FAS using a mixed model for a cross-
over study, similar to the primary analysis model. The
same statistical model specified above was also used
for an exploratory analysis undertaken to compare the
different doses and frequencies of olodaterol.
Safety end points were summarised descriptively using
the treated set (all randomised patients who were dis-
pensed study medication and were documented to have
taken at least one dose of investigational treatment).
Results
Patient population
A total of 206 patients at 36 sites in six countries (Austria,
Germany, Hungary, Slovakia, Slovenia and the USA) were
randomised (Table 1): the population comprised a rela-
tively even proportion of women to men (53 % versus
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never smoked. Overall, 199 patients (96.6 %) completed
the study (Fig. 2).
Efficacy
Lung function
Highly statistically significant improvements in FEV1
AUC0–24 response were observed with all doses and dose
frequencies of olodaterol compared to placebo at week 3
(p < 0.0001) (Table 2), with similar results demonstrated
for individual FEV1 values at all individual time points
(p < 0.0005) (Fig. 3).
For the within-crossover group comparisons of the
same total daily dose, the mean FEV1 AUC0–24 re-
sponse for treatment with olodaterol 2.5 μg BID
(0.213 L) was greater than for olodaterol 5 μg QD
(0.173 L; p = 0.0465; adjusted mean difference for 5 μg QD
versus 2.5 μg BID -0.040 L [95 % CI -0.080, -0.001]). There
was no evidence of a difference between treatment with
olodaterol 10 μg QD and 5 μg BID (p = 0.3388; adjusted
mean difference -0.019 L [95 % CI -0.059, 0.020]).
In the secondary, exploratory analysis of two different
total daily doses (i.e. parallel-group comparison), thereFig. 2 CONSORT diagram illustrating participant flow. Since this was a cros
the total number of patients is not the sum of the number of each pati
prematurely, the most frequent reason was non-compliance with the tr
AE: adverse eventwas no significant difference between mean FEV1
AUC0–24 response with olodaterol 5 μg BID and 2.5 μg
BID (p = 0.1631; adjusted mean difference 0.037 L
[95 % CI -0.015, 0.090]), while olodaterol 10 μg QD
provided a greater mean FEV1 AUC0–24 response than
olodaterol 5 μg QD (p = 0.0289; adjusted mean differ-
ence 0.059 L [95 % CI 0.006, 0.111]). Mean FEV1
AUC0–24 response was higher with olodaterol 5 μg BID
compared to olodaterol 5 μg QD (p = 0.0038; adjusted
mean difference 0.078 L [95 % CI 0.025, 0.130]).
The post hoc sensitivity analyses performed with placebo
split according to treatment sequence were consistent with
the primary analysis (p < 0.0001 for all comparisons with
placebo) and gave similar estimates for treatment effect.
Analysis of the key secondary end points of FEV1
AUC0–12 and AUC12–24 responses supported the out-
comes of the primary end point and provided additional
information from within the 24-h measurement period
for olodaterol QD and BID, indicating increased adjusted
mean FEV1 AUC12–24 response for BID versus QD of
the same daily dose, as would be expected (Table 2).
Adjusted mean FEV1 at individual time points are shown
in Additional file 1: Table S1.sover trial and every patient was supposed to receive three treatments,
ent on each treatment. Of the seven patients who discontinued
ial protocol (three patients). BID: twice daily; QD: once daily;
Table 2 Adjusted mean FEV1 AUC0–24, AUC0–12 and AUC12–24 responses at 3 weeks
Difference from placebo, L
End point Treatment, μg n Mean FEV1 AUC response, L (SE) Mean (SE) 95 % CI p value
FEV1 AUC0–24 response Placebo 200 0.022 (0.020)
Olodaterol 2.5 BID 99 0.213 (0.024) 0.191 (0.020) 0.152, 0.229 <0.0001
Olodaterol 5 QD 99 0.173 (0.024) 0.150 (0.020) 0.111, 0.189 <0.0001
Olodaterol 5 BID 100 0.250 (0.024) 0.228 (0.020) 0.190, 0.266 <0.0001
Olodaterol 10 QD 101 0.231 (0.024) 0.209 (0.020) 0.170, 0.247 <0.0001
FEV1 AUC0–12 response Placebo 200 0.052 (0.020)
Olodaterol 2.5 BID 99 0.242 (0.024) 0.190 (0.020) 0.150, 0.229 <0.0001
Olodaterol 5 QD 99 0.212 (0.024) 0.160 (0.020) 0.121, 0.199 <0.0001
Olodaterol 5 BID 100 0.266 (0.024) 0.214 (0.020) 0.175, 0.253 <0.0001
Olodaterol 10 QD 101 0.272 (0.024) 0.219 (0.020) 0.181, 0.258 <0.0001
FEV1 AUC12–24 response Placebo 201 -0.010 (0.020)
Olodaterol 2.5 BID 99 0.186 (0.025) 0.196 (0.022) 0.153, 0.238 <0.0001
Olodaterol 5 QD 99 0.135 (0.025) 0.144 (0.022) 0.102, 0.187 <0.0001
Olodaterol 5 BID 100 0.233 (0.025) 0.242 (0.022) 0.200, 0.285 <0.0001
Olodaterol 10 QD 101 0.189 (0.025) 0.198 (0.022) 0.156, 0.241 <0.0001
Common study baseline mean (SE): 2.571 (0.054) for all end points
FEV1 forced expiratory volume in 1 s, AUC0–24 area under the curve from 0 to 24 h, AUC0–12 area under the curve from 0 to 12 h, AUC12–24 area under the curve
from 12 to 24 h, SE standard error, CI confidence interval, BID twice daily, QD once daily
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2.5 μg BID versus 5 μg QD, but not with 5 μg BID ver-
sus 10 μg QD, was identified (Fig. 4a; Table 2). The ad-
justed mean difference from placebo in FEV1 AUC0–12
response ranged from 0.160 L (5 μg olodaterol QD; 95 %Fig. 3 Adjusted mean FEV1: individual time points from 0 to 24 h at 3 wee
daily; FEV1: forced expiratory volume in 1 sCI 0.121, 0.199) to 0.219 L (10 μg olodaterol QD; 95 %
CI 0.181, 0.258), while results for FEV1 AUC12–24 re-
sponse ranged from 0.144 L (5 μg olodaterol QD; 95 %
CI 0.102, 0.187) to 0.242 L (5 μg olodaterol BID; 95 %
CI 0.200, 0.285) (Fig. 4b). For both end points, anks. Analysis with imputation, full analysis set. BID: twice daily; QD: once
ab
Fig. 4 Difference versus placebo at 3 weeks of adjusted mean FEV1 AUC0–12 (a) and AUC12–24 (b). FEV1: forced expiratory volume in 1 s;
AUC0–12: area under the curve from 0 to 12 h; SE: standard error; BID: twice daily; QD: once daily; AUC12–24: area under the curve from 12 to 24 h
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observed with an increasing total daily dose of olodaterol
at both dosing frequencies (p < 0.0001 for all compari-
sons with placebo).
The analysis of FEV1 at all individual time points
assessed at each visit after 3 weeks of treatment showed
strong evidence of efficacy (p < 0.0005 for comparisons
with placebo) with all olodaterol doses and dosing fre-
quencies at all post-dosing points on the 24-h curve.
Assessment of mean FVC AUC0–24 response sup-
ported the results of the primary end point (Fig. 5), as
did peak and trough FEV1 and FVC responses (Table 3
and see Additional file 1: Table S2) and PEF AUC0–24(see Additional file 1: Table S3), peak and trough re-
sponses (data not shown).Other efficacy variables
All doses and dosing frequencies of olodaterol pro-
vided statistically significant improvements in mean
morning and evening PEF (from patient diaries) and
total Asthma Control Questionnaire scores at 3 weeks
compared to placebo (p < 0.0001 for all comparisons
with placebo) (see Additional file 1: Table S4). No
relevant differences were observed between different
doses and regimens.
Fig. 5 Adjusted mean FVC AUC0–24 at 3 weeks. FVC: forced vital capacity; AUC0–24: area under the curve from 0 to 24 h; SE: standard error;
BID: twice daily; QD: once daily
Table 3 Adjusted mean peak and trough FEV1 and FVC responses at 3 weeks
Difference from placebo, L
End point Treatment, μg n Mean FEV1/FVC response, L (SE) Mean (SE) 95 % CI p value
FEV1 peak response Placebo 201 0.227 (0.021)
Olodaterol 2.5 BID 99 0.410 (0.027) 0.183 (0.023) 0.138, 0.228 <0.0001
Olodaterol 5 QD 99 0.380 (0.027) 0.153 (0.023) 0.108, 0.198 <0.0001
Olodaterol 5 BID 100 0.449 (0.027) 0.222 (0.023) 0.177, 0.267 <0.0001
Olodaterol 10 QD 101 0.437 (0.026) 0.210 (0.023) 0.165, 0.255 <0.0001
FEV1 trough response Placebo 201 0.033 (0.022)
Olodaterol 2.5 BID 99 0.189 (0.027) 0.156 (0.024) 0.109, 0.203 <0.0001
Olodaterol 5 QD 99 0.134 (0.027) 0.101 (0.024) 0.054, 0.148 <0.0001
Olodaterol 5 BID 100 0.229 (0.027) 0.196 (0.024) 0.149, 0.243 <0.0001
Olodaterol 10 QD 101 0.205 (0.027) 0.172 (0.024) 0.125, 0.219 <0.0001
FVC peak response Placebo 201 0.246 (0.024)
Olodaterol 2.5 BID 99 0.382 (0.030) 0.136 (0.026) 0.084, 0.187 <0.0001
Olodaterol 5 QD 99 0.371 (0.030) 0.124 (0.026) 0.073, 0.176 <0.0001
Olodaterol 5 BID 100 0.390 (0.030) 0.144 (0.026) 0.093, 0.195 <0.0001
Olodaterol 10 QD 101 0.373 (0.029) 0.126 (0.026) 0.075, 0.177 <0.0001
FVC trough response Placebo 201 -0.013 (0.024)
Olodaterol 2.5 BID 99 0.096 (0.031) 0.110 (0.028) 0.055, 0.165 0.0001
Olodaterol 5 QD 99 0.079 (0.031) 0.092 (0.028) 0.037, 0.147 0.0010
Olodaterol 5 BID 100 0.105 (0.031) 0.118 (0.028) 0.063, 0.172 <0.0001
Olodaterol 10 QD 101 0.098 (0.031) 0.111 (0.028) 0.057, 0.166 <0.0001
Common study baseline mean (SE): 2.571 (0.054) for FEV1 and 3.849 (0.073) for FVC
FEV1 forced expiratory volume in 1 s, FVC forced vital capacity, SE standard error, CI confidence interval, BID twice daily, QD once daily
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The overall proportion of patients who reported at least
one AE while on treatment was 35.4 %. Incidence of AEs
was highest for 5 μg BID olodaterol and lowest for 10 μg
QD, although, in general, AEs were in a similar range
(placebo 16.4 %; olodaterol 2.5 μg BID and 5 μg QD
14.9 %; 5 μg BID 18.8 %; 10 μg QD 12.7 %) (Table 4).
Overall incidence of AEs by sex was 34.0 % for men and
36.7 % for women, with the largest difference reported
with placebo treatment (11.7 % of men versus 20.6 % of
women reporting any AE). Serious AEs were reported
for four patients in total (1.9 %): two patients (1.0 %) for
placebo, one patient in the washout period 4 days after
discontinuing 5 μg BID olodaterol treatment and one
patient 9 days after starting olodaterol 2.5 μg BID. None
was considered to be treatment-related.
Overall, the most frequently reported AEs were infec-
tions and infestations (14.1 %), with sinusitis the most
frequently reported AE within this category (2.4 % over-
all). Respiratory, thoracic and mediastinal disorders were
the second most frequently reported AE (9.2 %), with
the highest rate reported for placebo, at 4.5 %. Within
this category, the most common AE reported was
asthma (4.4 % overall) with the highest reporting fre-
quency of 2.0 % for placebo and olodaterol 5 μg BID
(Table 4).
A total of seven patients (3.4 %) were considered to







All AEs 33 (16.4) 15 (14.9) 15
Treatment-related AEs 2 (1.0) 0 1
AEs leading to discontinuation 0 1 (1.0) 0
Serious AEs 2 (1.0) 1 (1.0) 0
Specific AEs with an incidence >1 %
Asthma 4 (2.0) 1 (1.0) 1
Injury, poisoning and procedural
complications
2 (1.0) 3 (3.0) 0
Headache 5 (2.5) 1 (1.0) 2
Sinusitis 1 (0.5) 0 0
Nasopharyngitis 3 (1.5) 0 0
Musculoskeletal and connective
tissue disorders
0 2 (2.0) 1
Upper respiratory tract infection 3 (1.5) 1 (1.0) 0
Cystitis 1 (0.5) 0 0
Eye disorders 1 (0.5) 0 0
Rhinitis allergic 0 2 (2.0) 0
Skin and cutaneous tissue disorders 0 0 2
The preferred term ‘asthma’ summarises several lowest level terms; in the majority
AE adverse event, BID twice daily, QD once dailyTwo patients were receiving placebo (1.0 %; headache
and cough); two patients who had cough were receiving
olodaterol (one receiving 5 μg QD, one receiving 10 μg
QD; 1.0 % in both instances). Insomnia, palpitations and
asthma were reported by three patients taking 5 μg BID
olodaterol (3.0 %). No notable findings were reported via
assessment of laboratory parameters, vital signs and
electrocardiogram readings.
Discussion
The results of this study add support to the growing evi-
dence base that olodaterol delivered by Respimat® QD
provides effective 24-h bronchodilation in both COPD
and asthma [9–11, 13–16, 25]. This study was designed
to assess the efficacy of different daily doses and dose
frequencies of olodaterol versus placebo, and between
different doses and frequencies of olodaterol in an ex-
ploratory fashion, in patients with moderate to severe
persistent asthma after 3 weeks of treatment, thereby
providing additional information on the efficacy of QD
versus BID dosing.
Both total daily doses and all dosing frequencies of
olodaterol tested provided highly significant improve-
ments versus placebo in efficacy variables based on
pulmonary function tests, albeit with different 24-h
bronchodilatory profiles. Differences were seen be-
tween doses and posologies of olodaterol, with a








(14.9) 19 (18.8) 13 (12.7) 73 (35.4)
(1.0) 3 (3.0) 1 (1.0) 7 (3.4)
1 (1.0) 0 2 (1.0)
1 (1.0) 0 4 (1.9)
(1.0) 2 (2.0) 1 (1.0) 9 (4.4)
3 (3.0) 1 (1.0) 9 (4.4)
(2.0) 0 3 (2.9) 9 (4.4)
0 4 (3.9) 5 (2.4)
1 (1.0) 0 4 (1.9)
(1.0) 1 (1.0) 0 4 (1.9)
1 (1.0) 0 4 (1.9)
2 (2.0) 0 2 (1.0)
2 (2.0) 0 2 (1.0)
0 0 2 (1.0)
(2.0) 0 0 2 (1.0)
of cases, the reported level term was ‘exacerbation of asthma’
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tistically significant difference was observed between
olodaterol 5 μg BID and olodaterol 10 μg QD in the
morning.
As expected, the second daily dose in BID schedules
gave increased mean FEV1 AUC12–24 response versus
QD dosing at the same daily dose after 3 weeks of treat-
ment. However, while a higher mean FEV1 AUC0–12 re-
sponse might be anticipated for the QD dosing (as was
observed for mean area under the curve from 0 to 3 h
response at the start of the 3-week treatment period
[data not shown]), this was not observed.
Pre-dose morning FEV1 measurements at -1 h
and -10 min in this study were numerically higher for
both the BID posologies versus QD posologies but notably
for 2.5 μg olodaterol BID, hinting at a residual effect; how-
ever, further investigation would be required to fully
evaluate this potential effect. An inspection of the placebo
versus olodaterol time profiles confirms that the reported
circadian influence on lung function [26] is not abolished
but rather the level of bronchodilation is increased by
olodaterol treatment.
Interpretation of the exploratory data in the present
study should, however, take into consideration that the
study was designed to compare different doses and dos-
ing frequencies of olodaterol with placebo. Conse-
quently, it was not powered to examine statistical
differences between active treatments, nor was there any
adjustment made for such multiple treatment compari-
sons. As individual patients only received one total daily
dose, inter-patient variability also contributed to increas-
ing uncertainty in the estimation of effect-size compari-
sons of different daily doses in the parallel arms (wider
CIs). Therefore, as is generally true for Phase II studies,
any interpretation of the comparisons between different
doses and dose frequencies of olodaterol should be
undertaken with caution.
Although this study provided some information on the
difference in efficacy of different posologies of the same
daily dose of olodaterol on top of ICS, along with dem-
onstrating adequate short-term safety, further, longer-
term research would be required to fully examine the
optimum olodaterol dose regimen in patients with
asthma, possibly investigating patient type, combination
treatment and the effect of variations in the timing of
QD dosing (e.g. morning versus evening dosing).
The lung function efficacy of olodaterol versus placebo
has also been demonstrated by other Phase II olodaterol
trials carried out in asthma [20, 21]. O’Byrne et al. re-
ported results of their placebo-controlled, parallel-group
study in 426 patients (NCT00467740) at the American
Thoracic Society meeting in 2012 [20] and demonstrated
dose-dependent improvements in lung function with QD
olodaterol, although dose ordering was not consistentlyshown for each of the individual efficacy end points. While
the primary end point of trough FEV1 demonstrated nu-
merical improvement for all doses, including 5 and 10 μg
olodaterol, only the improvements observed in patients
receiving 20 μg olodaterol QD were statistically significant.
Evidence of dose ordering was observed in the pre-dose
morning PEF response, with dose-related improvements
also observed on the Asthma Control Questionnaire [20].
Due to lack of dose ordering seen for the primary end point
in this study, Beeh et al. conducted a similar study, but
using an incomplete-block crossover design, in 198 patients
(NCT01013753) [21]. This study also demonstrated highly
statistically significant improvements in FEV1 and PEF
response with all doses of olodaterol examined and clear
evidence of dose ordering [21].
The results of our study provide further evidence for
the dose ordering seen between 5 and 10 μg total daily
doses; the parallel-group comparison of 5 μg QD versus
10 μg QD for several FEV1 response assessments dem-
onstrates a dose response with increasing dose, and fur-
ther evidence for this relationship is supplied by the
comparison of 2.5 μg BID versus 5 μg BID. Indeed, a
dose response is also observed when doubling the dose
from 5 μg QD to 5 μg BID. When considered as a whole,
the weight of the current evidence from several oloda-
terol trials in asthma indicates a relevant dose-response
relationship between a total daily dose of 5 and 10 μg
olodaterol.
Increases in FVC observed with all doses of olodaterol
were lower than the increases seen with FEV1. This may
indicate the effect of olodaterol on peripheral airways, as
air trapping is often a feature of small-airway disease in
patients with severe asthma [27]. Indeed, bronchodilation
using high doses of albuterol has been demonstrated to
decrease residual volume:total lung capacity ratio while in-
creasing FVC in parallel, with improvements in FVC par-
tially responsible for increase in FEV1 [27].
A series of clinical studies has examined the dose
dependence and posology of olodaterol bronchodilatory
efficacy in COPD. A single-dose study [10] and a study
of 4-week QD treatment [11] have demonstrated 24-h
bronchodilation in COPD. In order to investigate
dosing frequency, a complete-block crossover study
(NCT00846768) investigated the 24-h bronchodilator
profile of different olodaterol regimens in 47 patients
with COPD [12]. Although it did not include a placebo
treatment, the study demonstrated statistically significant
improvements versus baseline for all doses and dose regi-
mens: 5 and 10 μg QD provided near-identical broncho-
dilation over a 24-h period, while 5 μg QD demonstrated
an improved bronchodilation profile versus 2 μg BID [12],
thus providing support for the further investigation of 5
and 10 μg QD in COPD [13–16, 28]. Olodaterol 5 μg QD
is now approved in several countries for the treatment of
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that olodaterol provides effective 24-h bronchodilation in
both asthma and COPD. The data in COPD provide a
clear rationale for QD schedules; the current data in
asthma are limited and less clear, although all doses and
schedules provided effective 24-h bronchodilation.
Thorough investigation of new LABAs in asthma is of
particular relevance due to the concerns over safety of this
class of agent. LABA monotherapy in asthma is contrain-
dicated to minimise the risk of serious exacerbations of
asthma and asthma-associated deaths [17]; it is for this rea-
son that patients in the present study were required to
continue taking ICS as background medication. To ensure
a full picture of the safety of new LABAs, the US Food and
Drug Administration also considered asthma safety data
when approving the LABA indacaterol in COPD at 75 μg
QD (a lower dose than the EU) [29]. With this in mind,
the current study demonstrated an acceptable short-term
safety profile for olodaterol in asthma on top of mainten-
ance ICS. Incidence of AEs was similar between olodaterol
and placebo, and ranged from 12.7 to 18.8 %. All three
studies in asthma conducted to date have shown olodaterol
to have consistent short-term safety and tolerability pro-
files, and have raised no safety concerns [20, 21], in line
with previous studies in COPD [11, 12].
In conclusion, in this posology study in patients with
moderate to severe asthma, while resulting in some dif-
ferences in 24-h bronchodilation profile, all daily doses
(5 and 10 μg) and dose frequencies (2.5 μg BID, 5 μg
QD, 5 μg BID, 10 μg QD) of olodaterol demonstrated
24-h bronchodilation superior to placebo in patients
with asthma on a background of inhaled steroids. These
data should be interpreted with caution, as further stud-
ies would be required in asthma before making clinical
decisions on optimal dosing and posology. No safety
concerns were identified and the short-term safety and
tolerability profiles of olodaterol were similar to those
seen in previous trials. Further, long-term research
would be required in order to fully examine the long-
term safety and optimum dose regimen of olodaterol in
patients with asthma.
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